Search results
Results from the WOW.Com Content Network
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone . [ 8 ]
Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. [3]
The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.
When it comes to drug pricing, European regulators are a tough sell. Just ask Johnson & Johnson . The U.K.'s National Institute for Health and Care Excellence, or NICE, took a pass on paying for ...
Here's the formula to calculate your Estimated Due Date using Naegele's rule : Date of Last Menstrual Period + 7 Days + 9 Calendar Months = Date of Estimated Date of Delivery. Example: LMP = 8 May 2020 +1 year = 8 May 2021 −3 months = 8 February 2021 +7 days = 15 February 2021
Lipinski's rule of five, also known as Pfizer's rule of five or simply the rule of five (RO5), is a rule of thumb to evaluate druglikeness or determine if a chemical compound with a certain pharmacological or biological activity has chemical properties and physical properties that would likely make it an orally active drug in humans.
A Florida teen who police claim previously killed his father in self-defense is accused of murdering his mother after allegedly telling her, “I’m not a psychopath.”. Collin Griffith, 17, was ...
REVLIMID net sales anticipated to be in the range of $4.1 billion to $4.2 billion, an increase of 9 to 12 percent year-over-year, 11 to 14 percent on a constant currency basis